The health and safety of patients who use Bayer products is our top priority.

Cipro® (ciprofloxacin) is a fluoroquinolone antibiotic, an important class of medications that treat a wide range of bacterial infections, many of which are serious and can be life-threatening. All medicines have potential side effects and the risks are communicated to physicians and patients in FDA-approved product labeling. The Cipro label contains FDA-approved language advising physicians and their patients about the potential side effects associated with the use of this therapy, including specific warnings about the risks of central nervous system and other psychiatric effects.

The safety and efficacy of Bayer's fluoroquinolones have been demonstrated in clinical trials involving more than 90,000 patients and extensive clinical experience in more than 800 million patients. Cipro was originally approved by the FDA in 1987 and is now widely available as a generic medication that is manufactured and supplied widely throughout the United States by several companies.

Bayer closely monitors the safety and efficacy of its fluoroquinolones on an ongoing basis, as we do with all of our products. As with any prescription medication, Bayer encourages patients to discuss the risks and benefits of these medications with their healthcare provider.

Best regards,

David Patti
Deputy Director, U.S. Pharmaceuticals
Product Communications, Specialty Franchise